ZUMA-1: safety and efficacy of axicabtagene in refractory non-Hodgkin lymphoma patients

0 Views
administrator
administrator
07/09/23

Sattva Neelapu, MD, University of Texas MD Anderson Cancer Center, Houston, TX, updates us on the ZUMA-1 study (NCT02348216), investigating the safety and efficacy of axicabtagene ciloleucel, CAR-T cell therapy, in relapsed, aggressive follicular lymphoma and marginal zone lymphoma patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next